Omniose was founded in 2016 based on the pioneering glycoconjugation discoveries of our scientific founders Mario Feldman and Christian Harding through a scientific collaboration that characterized a new class of conjugating enzymes. The research operations were established at BioGenerator Labs in St. Louis and the company was previously known as VaxNewMo. Omniose has been awarded $11.8 million in grants from the US NIAID for use of our platform technology to develop vaccines against Group B Streptococcus, Klebsiella pneumoniae, and Streptococcus pneumoniae.
In January 2024, the company announced an exclusive collaboration agreement with AstraZeneca for up to three years to research potential vaccines for bacterial pathogens.
Company Details
- Employees
- 18
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.omniose.com
Omniose Questions
Omniose's website is http://www.omniose.com
Omniose's LinkedIn profile is https://www.linkedin.com/company/omniose
Omniose has
18 employees.
View email and phone details for 18
employees at Omniose.
Omniose's industry is
Biotechnology Research
Omniose's top competitors are
Vir Biotechnology, Inc.,
Solis Agrosciences,
Cortex Innovation District,
Biostl,
Wugen,
Geneoscopy,
Biogenerator Ventures,
Covercress Inc.,
Panome Bio,
Vaxnewmo, Llc.
Omniose's categories are Biotechnology Research
